Active substance |
Adalimumab |
Holder |
AbbVie |
Statut |
Closed |
Indication |
Treatment of paediatric chronic non-infectious anterior uveitis patients (from 2 years of age) who have had an inadequate response to conventional therapy including topical corticosteroid and an immunomodulator, or who are intolerant to or have contraindications for such therapies |
Documents publics |
|
Last update |
04/12/2018 |
Humira
Last updated on 13/02/2024